Welcome to the POTP board, the DPP-IV company

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical
Welcome to the POTP board, the DPP-IV company

An SI Board Since July 2006

Posts	SubjectMarks	Bans	Symbol
90	11	0	POTP

Emcee: rareearth42	Type: Moderated

Introduction Market Data Compact

I'm fascinated that this little company, with talabostat in phase 3 trials for NSCLC, which had 2 CRs out of 42 patients in phase 2, is still essentially unknown among institutional and private investors.

Talabostat is val-boro-pro, and broadly inhibits DPPs, particularly DPP-IV, FAP, DPP-8 and DPP-9. The concept as an anti-cancer drug is that it will interfere with the desmoplastic response to tumors, which in some cases may be permissive for growth of the tumor, and the inhibition of the -8 and -9 will augment cytokine levels locally, which may in turn increase an anti-tumor immune response. At this point, it's all speculative and we'll just have to see what happens in the trials when they're done in 2007.

Comments welcome.

RE42

Go to reply# or date (mm/dd/yy):

Reply	Message Preview	From	Recs	Posted
90	Point about to become Dara. Tiny Dara going public by crawling into another bi	rkrw	-	1/28/2008
89	At 3.2 cents per share I won't bet against you :-)	rkrw	-	9/24/2007
88	<i>Wonder if they'll find a buyer for their dpp inhibitors.</i>	Biomaven	-	9/24/2007
87	They did keep them on as part time consultants (see 8k). But I'm sure this w	rkrw	-	7/28/2007
86	>>Point Therapeutics Announces Further Management Reductions Friday July	tuck	-	7/28/2007
85	POTP Cut more than planned. Might buy them another month. Night falls in Octobe	pgo-neil	-	7/12/2007
84	POTP cuts 60% of workforce to buy time. Took them 10 days to respond after tria	pgo-neil	-	5/31/2007
83	<demonstrated significantly lower overall survival than the placebo arm.>	kenhott	-	5/22/2007
82	Yet another small, open label, non placebo controlled phase II bombing in phase	rkrw	-	5/21/2007
81	<reply> Here is the revised PR: CORRECTING and REPLACING Point Therapeut	kenhott	-	5/16/2007
80	This is a classic hail mary play.	rkrw	-	5/15/2007
79	>I would think this unscheduled peek would have to be coordinated and approve	former_pgs	-	5/15/2007
78	Hi Jim, Thanks for the PR notice... Obviously they are scrambling for some po	pgo-neil	-	5/15/2007
77	Make or break. Press Release Source: Point Therapeutics, Inc. Point Therapeu	rkrw	-	5/15/2007
76	Excellent pick-up last month, Graham.. <i>Updated Risk Filing with SEC lo	zeta1961	-	3/1/2007
75	Point Therapeutics Provides Clinical Update Thursday March 1, 7:25 am ET BOSTON	kenhott	-	3/1/2007
74	Updated Risk Filing with SEC looks a little more scary. They approach Going Con	pgo-neil	-	2/8/2007
73	The only news of which I'm aware is this article from TheStreet.con thestre	rareearth42	-	1/19/2007
72	POTP has traded 2.3 million shares today. That is HUGE volume for this company.	z3peru	-	1/19/2007
71	POTP to continue phase 2 Pancreatic trials. About 10% response rate [N=21, good	pgo-neil	-	1/12/2007
70	BOSTON--(BUSINESS WIRE)--Point Therapeutics, Inc. (NASDAQ: POTP - News) today pr	nigel bates	-	1/12/2007
69	CIBC World Markets: On 12/21, POTP reported final results from the ph.II trial	idos	-	12/23/2006
68	It's sure getting hit hard. My concern would be the endpoints of the nsclc	former_pgs	-	11/26/2006
67	former_pgs, As a fellow former pgs, in the generic sense, I remain stumped rega	rareearth42	-	11/26/2006
66	OT: MCU >as far as thinking you can take enough b-6 to get enough P5P into y	former_pgs	-	11/22/2006

Go to reply# or date (mm/dd/yy):